

PERSONAL INFORMATION

Sabina Murgioni (Italy) sabina.murgioni@iov.veneto.it

Nationality Italian

POSITION

Medical specialist in Medical Oncology

WORK EXPERIENCE

10/2005–9/2008

AOU Cagliari Hospital, Monserrato (Italy)

Attendance c/o Medical Oncology II as an internal student, then as a medical intern participating departmental activities and conducting the Thesis

9/2008–5/2010

ASL n°4, Lanusei (Italy)

Medical territorial continuity service at the in Gairo Santa Elena

1/1/2014–31/10/2014

Dottor Antonio Marchi, Sarroch (Italy)

Emergency doctor c/o oil facilities of Sarlux (ex Eni Versalis) e Sindial

1/11/2014–30/4/2015

Milano (Italy)

Attendance at the Medical Oncology Unit and Gastrointestinal Tumors Neuroendocrine IRCCS European Institute of Oncology in Milan.

1/7/2015–3/7/2015

ASL n°8 Cagliari, Muravera (Italy)

Substitution in outpatient specialist activity regimen for total of 21 hours

11/6/2015–28/12/2015

ASL n°4 Lanusei, Lanusei (Italy)

Substitution in outpatient specialist activity regimen for total of 360 hours

1/9/2015–30/11/2015

ASL n° 4 Lanusei, Tertenia (Italy)

Medical territorial continuity service in Tertenia, ASL n 4 (Lanusei).

1/12/2015–15/12/2015

ASL n° 3 Nuoro, Siniscola (Italy)

Substitution in outpatient specialist activity regimen for total of 20 hours

1/1/2016–31/3/2016

ASL n° 4 Lanusei, Tortoli (Italy)

Medical territorial continuity service in Tortoli, ASL n 4 (Lanusei).

1/3/2016–Present

Medical Oncologist

Medical Oncology 1- IOV, Padova (Italy)

EDUCATION AND TRAINING

5/2010–5/2015

University of Cagliari, Cagliari (Italy)

Specialization in Medical Oncology dated 05.27.2015. Thesis entitled: "integrated multimodal treatment of patients with advanced neuroendocrine pancreatic cancer: 15-year IEO series.

7/2008

Cagliari (Italy)

In the first session (July) I supported the evidence of the State examination for the qualification to the medical profession successfully.

2000–12/2007

University of Cagliari, Cagliari

Degree from the 19/12/2007.

Thesis entitled: "cardiotoxicity of anthracyclines in the short and long term in the adjuvant and neoadjuvant treatment of breast cancer"

1995–2000

Lanusei

Scientific State High School Leonardo da Vinci in Lanusei (NU)

PERSONAL SKILLS

Mother tongue(s)

Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B1	B1	A2	A2	B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

Job-related skills

Since May 2016 Certificate ICH E6 GCP

Digital competence

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Independent user				

Digital competences - Self-assessment grid

Driving licence B1

ADDITIONAL INFORMATION

Scientific publications

- Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Suenaga M1, Schirripa M1, Cao S2, Zhang W1, Yang D2, Murgioni S3, Rossini D4, Marmorino F4, Mennitto A5, Ning Y1, Okazaki S1, Berger MD1, Miyamoto Y1, Gopez R1, Barzi A1, Yamaguchi T6, Loupakis F3, Lenz HJ1. 1Division of Medical Oncology Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA.2Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA.3Medical Oncology 1 Unit, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy.4Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy.5Medical Oncology Department, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.6Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Ann Oncol. 2017 Feb 9. doi: 10.1093/annonc/mdx035.
- Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report. Ungaro A1, Orsi F1, Casadio C2, Galdy S1, Spada F1, Cella CA1, Tonno CD2, Bonomo G3, Vigna PD3, Murgioni S1, Frezza AM1, Fazio N1. Gastrointestinal Medical Oncology and Neuroendocrine Tumors Unit European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Critical Reviews in Oncology/Hematology. Ecancermedalscience. 2016 Apr 21;10:635. doi: 10.3332/ecancer.2016.635. eCollection 2016.
- Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials Salvatore Galdy*, Chiara Alessandra Cella, Francesca Spada, Sabina Murgioni, Anna Maria Frezza, Simona Paola Ravenda, Maria Giulia Zampino, Nicola Fazio Gastrointestinal Medical Oncology and Neuroendocrine Tumors Unit European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Critical Reviews in Oncology/Hematology.
- Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside. Chiara Alessandra Cella, Saverio Minucci, Francesca Spada, Salvatore Galdy, Mohamed Elgendy, Paola Simona Ravenda, Maria Giulia Zampino, Sabina Murgioni, Nicola Fazio. Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy. Department of Experimental Oncology, European Institute of Oncology, Milan, Italy, Department of Biosciences, University of Milan, Italy. Cancer Treatment Reviews; November 2015; Volume 41, Issue 9, Pages 754–760
- Everolimus (EV) related toxicity in metastatic breast cancer (MBC). A single Institution experience. Murgioni S, Atzori F, Notari F, Ziranu P, Cugudda S, Mascia R, Pusceddu V, Frau B and Ionta MT. Department of Medical Oncology, Hospital-University, Cagliari, Italy Abstract n° A59 Aiom 2014.
- Bevacizumab related toxicity in metastatic colorectal cancer (mcr). a single institution experience. (Ziranu P, Frau B, Puzzone M, Murgioni S, Muntoni M, Cau M.C., Mascia R, Pusole G, Dessì A, Cogoni C, Cubeddu A, Loi C, Orgiano L, Defraia S, Serici C, Astara G, Atzori F, Massa E, Madeddu C, Pusceddu V and Ionta MT. Department of medical oncology, hospital-university, Cagliari, Italy) abstract n° a40. Aiom 2013.

- Activity of electrochemotherapy (ect) in the treatment of cutaneous and subcutaneous metastases of adenocarcinoma of the rectum. a case report.(solinas c, cabula c, frau b, notari f, cugudda s, murgioni s, muntoni m, marongiu m, ziranu p, pala l lepori s, cau mc, puzzoni m, demurtas l, dessi a, atzori f, pusceddu v, ionta mt department of oncologic surgery, oncologic hospital a. businco – Cagliari. Department of medical oncology, hospital-university – cagliari) abstract Aiom 2013

- Dose-dense neoadjuvant chemotherapy in locally advanced breast cancer. long term results of an italian multicenter co-operative retrospective study f.notari¹, s.murgioni¹, s.cugudda¹, m.marongiu¹, c.solinas¹, l.pala¹, s.lepori¹, l.demurtas¹, n.olmeo², e.valle³, g.sarobba⁴, f.atzori¹, b.frau¹, f.m.tanca¹, s.tolu¹, m.g.zedda¹, s. defraia¹, c.serci¹, m.fanzecco⁵, m.t.ionta¹ ;¹department of medical oncology, hospital-university, cagliari, italy; ² department of medical oncology, civil hospital, azienda sanitaria locale 1, sassari, italy; ³department of medical oncology, oncologic hospital, cagliari, italy; ⁴department of medical oncology, hospital-university, sassari, italy; ⁵department of medical science, cagliari, Italy. Poster Aiom 2013. Annals of Oncology Volume 19, 2008 Supplement 9; 10th National Congress of Medical Oncology 11-14 October, 2008: *Long-Term results of monitoring left ventricular ejection fraction (L-VEF) after epirubicin treatment in early breast cancer patients, our experience.*

- Prognostic role of ER+ associated with other clinical biological features in T4 breast cancer achieving less than a pathological complete response (Department of Medical Oncology, University and A.O.U. of Cagliari). POSTER VII Giornata Scientifica 18 giugno 2010, Università degli studi di Cagliari.

- Prognostic role of ER+ associated with other clinical biological features in T4 breast cancer achieving less than a pathological complete response (Department of Medical Oncology, University and A.O.U. of Cagliari). ABSTRACTXII NATIONAL CONGRESS OF MEDICAL ONCOLOGY November 6-8, 2010: Rome, Italy

The undersigned authorizes, pursuant to Legislative Decree. N. 196/2003's use and processing of personal data.

Dott.ssa Sabina Murgioni